Guardant Health [GH] vs Danaher [DHR] Detailed Stock Comparison
Guardant Health
NASDAQ
Loading...
Danaher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Guardant Health wins in 8 metrics, Danaher wins in 10 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Guardant Health | Danaher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -15.23 | 42.58 | Guardant Health |
| Price-to-Book Ratio | -22.03 | 2.74 | Guardant Health |
| Debt-to-Equity Ratio | -4.37 | 35.45 | Guardant Health |
| PEG Ratio | -20.01 | 23.93 | Guardant Health |
| EV/EBITDA | -18.07 | 21.17 | Guardant Health |
| Profit Margin (TTM) | -49.93% | 14.21% | Danaher |
| Operating Margin (TTM) | -45.75% | 20.12% | Danaher |
| EBITDA Margin (TTM) | N/A | 20.12% | N/A |
| Return on Equity | 312.48% | 6.68% | Guardant Health |
| Return on Assets (TTM) | -19.57% | 4.01% | Danaher |
| Free Cash Flow (TTM) | $-274.94M | $5.30B | Danaher |
| 1-Year Return | 87.00% | -25.19% | Guardant Health |
| Price-to-Sales Ratio (TTM) | 8.16 | 5.98 | Danaher |
| Enterprise Value | $7.57B | $159.22B | Danaher |
| EV/Revenue Ratio | 9.14 | 6.63 | Danaher |
| Gross Profit Margin (TTM) | 65.01% | 59.35% | Guardant Health |
| Revenue per Share (TTM) | $7 | $33 | Danaher |
| Earnings per Share (Diluted) | $-3.35 | $4.71 | Danaher |
| Beta (Stock Volatility) | 1.44 | 0.76 | Danaher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Guardant Health vs Danaher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Guardant Health | 7.62% | 30.93% | 6.71% | 30.11% | 22.14% | 70.70% |
| Danaher | 1.04% | 1.76% | -0.06% | 2.95% | -1.44% | -12.73% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Guardant Health | 87.00% | 0.09% | -36.54% | 85.72% | 85.72% | 85.72% |
| Danaher | -25.19% | -24.02% | 10.43% | 228.20% | 706.11% | 967.38% |
Performance & Financial Health Analysis: Guardant Health vs Danaher
| Metric | GH | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $6.76B | $143.61B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 4,168,170 | 4,555,780 |
| 90 Day Avg. Volume | 2,645,913 | 4,340,510 |
| Last Close | $54.23 | $200.56 |
| 52 Week Range | $20.14 - $54.62 | $171.00 - $279.90 |
| % from 52W High | -0.71% | -28.35% |
| All-Time High | $181.07 (Feb 08, 2021) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -70.05% | -32.26% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.31% | 0.03% |
| Quarterly Earnings Growth | 0.31% | -0.39% |
| Financial Health | ||
| Profit Margin (TTM) | -0.50% | 0.14% |
| Operating Margin (TTM) | -0.46% | 0.20% |
| Return on Equity (TTM) | 3.12% | 0.07% |
| Debt to Equity (MRQ) | -4.37 | 35.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.45 | $73.10 |
| Cash per Share (MRQ) | $4.19 | $4.13 |
| Operating Cash Flow (TTM) | $-238,546,000 | $6.17B |
| Levered Free Cash Flow (TTM) | $-131,174,000 | $3.88B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Guardant Health vs Danaher
| Metric | GH | DHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -15.23 | 42.58 |
| Forward P/E | -20.01 | 23.93 |
| PEG Ratio | -20.01 | 23.93 |
| Price to Sales (TTM) | 8.16 | 5.98 |
| Price to Book (MRQ) | -22.03 | 2.74 |
| Market Capitalization | ||
| Market Capitalization | $6.76B | $143.61B |
| Enterprise Value | $7.57B | $159.22B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.14 | 6.63 |
| Enterprise to EBITDA | -18.07 | 21.17 |
| Risk & Other Metrics | ||
| Beta | 1.44 | 0.76 |
| Book Value per Share (MRQ) | $-2.45 | $73.10 |
Financial Statements Comparison: Guardant Health vs Danaher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GH | DHR |
|---|---|---|
| Revenue/Sales | $203.47M | $5.74B |
| Cost of Goods Sold | $74.72M | $2.23B |
| Gross Profit | $128.75M | $3.51B |
| Research & Development | $88.52M | $379.00M |
| Operating Income (EBIT) | $-111.04M | $1.27B |
| EBITDA | $-83.84M | $1.87B |
| Pre-Tax Income | $-94.87M | $1.13B |
| Income Tax | $290,000 | $175.00M |
| Net Income (Profit) | $-95.16M | $954.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GH | DHR |
|---|---|---|
| Cash & Equivalents | $698.57M | $1.99B |
| Total Current Assets | $927.03M | $9.53B |
| Total Current Liabilities | $225.75M | $6.65B |
| Long-Term Debt | $1.28B | $15.98B |
| Total Shareholders Equity | $-250.79M | $50.86B |
| Retained Earnings | $-2.67B | $44.91B |
| Property, Plant & Equipment | $140.50M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GH | DHR |
|---|---|---|
| Operating Cash Flow | $-49.41M | $1.47B |
| Capital Expenditures | $-4.46M | $-239.00M |
| Free Cash Flow | $-67.15M | $1.05B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-45.01M | $-1.08B |
Short Interest & Institutional Ownership Analysis
| Metric | GH | DHR |
|---|---|---|
| Shares Short | 9.58M | 7.84M |
| Short Ratio | 4.80 | 2.08 |
| Short % of Float | 0.08% | 0.01% |
| Average Daily Volume (10 Day) | 4,168,170 | 4,555,780 |
| Average Daily Volume (90 Day) | 2,645,913 | 4,340,510 |
| Shares Outstanding | 123.99M | 719.10M |
| Float Shares | 119.55M | 637.22M |
| % Held by Insiders | 0.05% | 0.11% |
| % Held by Institutions | 0.99% | 0.83% |
Dividend Analysis & Yield Comparison: Guardant Health vs Danaher
| Metric | GH | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |